Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: A pilot study
Autore:
Lhomme, C; Brault, PH; Bourhis, JH; Pautier, P; Dohollou, N; Dietrich, PY; Akbar-Zadeh, G; Lucas, C; Pico, JL; Hayat, M;
Indirizzi:
Inst Gustave Roussy, Med Gynecol Oncol Unit, F-94805 Villejuif, France Inst Gustave Roussy Villejuif France F-94805 , F-94805 Villejuif, France
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 5, volume: 42, anno: 2001,
pagine: 1033 - 1041
SICI:
1042-8194(200109/10)42:5<1033:POMWL(>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
GONADOTROPIN-RELEASING-HORMONE; BONE-MARROW TRANSPLANTATION; PREMENOPAUSAL WOMEN; MINERAL DENSITY; ORAL-CONTRACEPTIVES; LEUPROLIDE ACETATE; ACUTE-LEUKEMIA; YOUNG-WOMEN; HYPERMENORRHEA; THERAPY;
Keywords:
thrombocytopenia; gonadotropin-releasing hormone agonist; menstruation; progestins;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
35
Recensione:
Indirizzi per estratti:
Indirizzo: Lhomme, C Inst Gustave Roussy, Med Gynecol Oncol Unit, 39 Rue Camille Desmoulins, F-94805 Villejuif, France Inst Gustave Roussy 39 Rue Camille Desmoulins Villejuif France F-94805
Citazione:
C. Lhomme et al., "Prevention of menstruation with leuprorelin (GnRH agonist) in women undergoing myelosuppressive chemotherapy or radiochemotherapy for hematological malignancies: A pilot study", LEUK LYMPH, 42(5), 2001, pp. 1033-1041

Abstract

Vaginal bleeding during aplasia can induce transfusion support, infection and discomfort. Oral and intramuscular hormonotherapy can be toxic and/or difficult to manage (mucositis). This single-center pilot study evaluated the efficacy and safety of leuprorelin (L) in preventing heavy vaginal bleeding in 20 nonmenopausal women with leukemia, lymphoma or myeloma and foreseable therapy-induced thrombocytopenia. Until platelet recovery, patients received subcutaneous injections of L, with concomitant nomegestrol acetate (NA) during the first 35 days to prevent flare-up. Median age was 33 years (18 - 48). Platelet nadir was < 20 x 10(9)/1 in 17patients; 103 L injections were performed (median per patient: 4 [1 - 14]). No moderate or severe adverse event was related to hormonal therapy. Seventeen patients did not experience any clinically or therapeutically relevant bleeding. Eleven spottings and 8 metrorrhagias (mean duration : 3 days) occurred in I I patients, requiring enhanced NA in 3 cases (baseline platelet count was < 20 x 10(9)/1 in 1 pt, premature termination of NA [the singleplatelet transfusion for metrorrhagia] in 1 pt, and endometrial hyperplasia (EH) in the third). In patients without EH, only 5 spottings were observed after the third injection, without neither clinical nor therapeutic impact (63 injections). In conclusion, leuprorelin administration is safe and effective in preventing vaginal bleeding. The sustained-release form and subcutaneous administration offer quality of life advantages.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 04:15:42